04 Nov2014
FDA approve first US vaccine for meningococcal disease serogroup B
The first vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B has been approved for license in US, the Food and Drug Administration have announced.
After receiving three doses of Trumenba, 82% of the participants had antibodies in their blood that killed four different serogroup B strains.
Neisseria meningitidis can be transmitted from person to person by coughing, kissing or sharing eating utensils. The bacteria infect the bloodstream and the lining surrounding the brain and the spinal cord, causing meningococcal disease.
ROCHESTER, Minn. – We’re taking you inside the research labs at Mayo Clinic, where some of the most cutting edge studies are happening as we speak.